{"id":"kps-0373","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, allowing excess glucose to be excreted in urine. This mechanism lowers blood glucose levels independently of insulin secretion and has been associated with additional cardiovascular and renal protective effects in diabetic patients.","oneSentence":"KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:04.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07040137","phase":"PHASE3","title":"Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration","status":"RECRUITING","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Spinocerebellar Degeneration","enrollment":142},{"nctId":"NCT02889302","phase":"PHASE3","title":"An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2016-11-15","conditions":"Spinocerebellar Degeneration","enrollment":203},{"nctId":"NCT01970098","phase":"PHASE3","title":"A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2013-10-09","conditions":"Spinocerebellar Degeneration","enrollment":374},{"nctId":"NCT01970137","phase":"PHASE3","title":"A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""},{"nctId":"NCT01970111","phase":"PHASE3","title":"An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""},{"nctId":"NCT01970124","phase":"PHASE3","title":"A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":""},{"nctId":"NCT01384435","phase":"PHASE2","title":"A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"SCD","enrollment":200},{"nctId":"NCT01004016","phase":"PHASE2","title":"A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":20},{"nctId":"NCT00863538","phase":"PHASE2","title":"Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Spinocerebellar Degeneration","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KPS-0373","genericName":"KPS-0373","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KPS-0373 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}